Close Menu

NEW YORK (GenomeWeb) – OpGen plans to offer $6.5 million of its common stock in a public offering, according to a preliminary prospectus filed with the US Securities and Exchange Commission on Friday.

The company has not priced its offering or said when it plans to make the offering. Net proceeds are expected to be about $5.8 million, it said in its SEC document, and will go toward R&D and regulatory activities in support of OpGen's anticipated 510(k) submission to the US Food and Drug Administration for its Acuitas AMR Gene Panel test and the Acuitas Lighthouse Software.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The UK and the European Union have come to a sticking point in the negotiation of how the UK might remain involved in the Horizon Europe research program, the Guardian reports.

The New York Times reports that experts pushed during a meeting of an FDA advisory board for the agency to require more safety data from SARS-CoV-2 vaccine trials.

The Washington Post reports Moderna expects that it will have enough data on its candidate SARS-CoV-2 vaccine to submit to regulatory authorities by mid-November.

In Science this week: ANXA11 variants affect calcium homeostasis and stress granule disassembly in ALS, and more.